Search Within

Margaret Kathleen Callahan

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (5)
Groups
  1. Advanced Practice Providers (18)
  2. Department of Medicine (18)
  3. Melanoma and Immunotherapeutics Service (18)
  4. Nursing (18)
  5. Solid Tumor Oncology Division (18)
  6. GSK Faculty (13)

More Groups

People
  1. Jedd Wolchok (13)
  2. Ruthann Gordon (11)
  3. Michael Postow (10)
  4. Alexander Lesokhin (7)
  5. Neil Segal (6)
  6. Yelena Shames (6)

More People

Years
  1. 2020 (1)
  2. 2018 (2)
  3. 2017 (3)
  4. 2016 (2)
  5. 2014 (4)
  6. 2013 (2)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. New England Journal of Medicine (2)
  3. Annals of Oncology (1)
  4. Asia-Pacific Journal of Clinical Oncology (1)
  5. Cancer (1)
  6. Cancer Immunology Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. Massachusetts Medical Society (2)
  3. Oxford University Press (2)
  4. Wiley Blackwell (2)
  5. American Association for Cancer Research (1)
  6. Biomed Central Ltd (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical implications of drug-induced liver injury in early-phase oncology clinical trials
    Journal Article

    Mondaca, S. P.; Liu, D.; Flynn, J. R.; Badson, S.; Hamaway, S.; Gounder, M. M.; Khalil, D. N.; Drilon, A. E.; Li, B. T.; Jhaveri, K. L.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade
    Meeting Abstract

    Santomasso, B.; Haggiagi, A.; Malani, R.; Maher, C. A.; Holder, J. N.; Shames, Y.; Wilcox, J.; Flynn, J.; Briggs, S.; Panageas, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.; Santomasso, B.
    Neurology (2018)

    Fulltext@MSK | Save
  • Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Santomasso, B.; Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • The development of neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Santomasso, B.; Callahan, M.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save